… In addition to dopaminergic neuropathology, there is … with dopamine system dysfunction
and/or dopaminergic neuronal … process affecting dopaminergic and non-dopaminergic systems (…

… dosing and sedation, we reduce or change the offending drug. We compromise motor control
by reducing dopaminergic drugs only among the subset of patients with intolerance to all …

… converted centrally to dopamine, replacing the neurotransmitter deficient in Parkinson disease.
Outside the … Anticholinergic drugs and amantadine act on postsynaptic receptors for other …

… In order to evaluate the relationship between the dose of dopaminergic drugs and the
development of an ICRB, we conducted three separate multivariate logistic regression analyses. …

… that can provide continuous dopaminergic stimulation, or … dopamine agonists such as
pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug …

… In this Review, we discuss the emerging non-dopaminergic therapies for PD with a focus
on disease modification and treatment of motor symptoms. We examine pharmacological …

… to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. …
AJ Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine …

… to take dopaminergic drugs becomes pathologically … leads to compulsive dopaminergic drug
use 1,2 —the dopamine … brain dopamine systems mediating reward by dopaminergic drugs …

… hypokinesia of psychiatric patients treated with the drug. The conclusions that dopamine is
involved in motor control, that large amounts of dopamine in the corpus striatum indicate an …

… Continuous dopaminergic stimulation is a therapeutic strategy … of Parkinson's disease, which
proposes that dopaminergic agents that provide continuous stimulation of striatal dopamine …